U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H31Cl2N7O3.H3O4P
Molecular Weight 658.4715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INFIGRATINIB PHOSPHATE

SMILES

CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=Nc4c(c(cc(c4Cl)OC)OC)Cl)O.OP(=O)(O)O

InChI

InChIKey=GUQNHCGYHLSITB-UHFFFAOYSA-N
InChI=1S/C26H31Cl2N7O3.H3O4P/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28;1-5(2,3)4/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31);(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C26H31Cl2N7O3
Molecular Weight 560.4763
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://adisinsight.springer.com/drugs/ | DOI: 10.1158/2159-8290.CD-NB2014-057 | http://meetinglibrary.asco.org/content/159420-173

Infigratinib (BGJ398), a potent, orally bioavailable, small-molecule pan-FGFR kinase inhibitor. FGFR genetic alterations are the most significant predictors for BGJ398 sensitivity. It is currently in phase 2 trials for Cholangiocarcinoma, Glioblastoma and Solid tumors. Detected adverse events were hyperphosphatemia, fatigue, constipation, cough and nausea. Other adverse events were generally mild and included stomatitis, hair loss, decreased appetite, and fatigue.

Originator

Curator's Comment:: # Novartis

Approval Year

TargetsConditions
PubMed

PubMed

TitleDatePubMed
Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.
2016 Oct
Inhibition of FGF Signalling Pathway Augments the Expression of Pluripotency and Trophoblast Lineage Marker Genes in Porcine Parthenogenetic Blastocyst.
2016 Oct
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
2017 Jan 10
Patents

Sample Use Guides

1 x 100 mg and 1 x 25 mg capsules once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle).
Route of Administration: Oral
BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:24:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:24:15 UTC 2021
Record UNII
58BH47BV6S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INFIGRATINIB PHOSPHATE
WHO-DD  
Common Name English
UREA, N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1-PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYL-, PHOSPHATE (1:1)
Systematic Name English
TRUSELTIQ
Brand Name English
BGJ-398 PHOSPHATE
Code English
INFIGRATINIB PHOSPHATE [WHO-DD]
Common Name English
N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-(4-(4-ETHYLPIPERAZIN-1-YL)ANILINO)PYRIMIDIN-4-YL)-N-METHYLUREA PHOSPHATE (1:1)
Common Name English
INFIGRATINIB MONOPHOSPHATE
Common Name English
INFIGRATINIB PHOSPHATE [USAN]
Common Name English
Code System Code Type Description
CAS
1310746-10-1
Created by admin on Fri Jun 25 21:24:15 UTC 2021 , Edited by admin on Fri Jun 25 21:24:15 UTC 2021
PRIMARY
NCI_THESAURUS
C175088
Created by admin on Fri Jun 25 21:24:15 UTC 2021 , Edited by admin on Fri Jun 25 21:24:15 UTC 2021
PRIMARY
DRUG BANK
DBSALT002096
Created by admin on Fri Jun 25 21:24:15 UTC 2021 , Edited by admin on Fri Jun 25 21:24:15 UTC 2021
PRIMARY
FDA UNII
58BH47BV6S
Created by admin on Fri Jun 25 21:24:15 UTC 2021 , Edited by admin on Fri Jun 25 21:24:15 UTC 2021
PRIMARY
PUBCHEM
56669626
Created by admin on Fri Jun 25 21:24:15 UTC 2021 , Edited by admin on Fri Jun 25 21:24:15 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY